Zentalis Pharmaceuticals ZNTL 深 沪

Zentalis Pharma Q1 EPS $(0.50) Misses $(0.47) Estimate

Zentalis Pharma (NASDAQ:ZNTL) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.47) by 6.38 percent. This is a 25.37 percent increase over losses of $(0.67) per share from

05-13 05:18

Zentalis Advances Azenosertib with New Trial Updates

Zentalis Pharmaceuticals ( ($ZNTL) ) has provided an announcement. On May 12, 2...

05-13 04:49

Zentalis Pharmaceuticals Doses First Patient In Phase 3 ASPENOVA Clinical Trial

Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy now enrollingASPENOVA designed as confirmatory study to support DENALI Phase 2 accelerated approval pathway, pending FDA

05-05 20:10

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

05-05 12:00

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals granted 26,000 non-qualified stock options to a newly hired employee under its 2022 Inducement Plan. The options, exercisable at $4.09 per share, vest over four years with 25% after one year and the remaining 75% in monthly installments over the next three years, contingent on continued employment. Zentalis is a clinical oncology company focused on developing a first-in-class WEE1 inhibitor for ovarian cancer treatment.

05-01 21:30

Zentalis Pharmaceuticals Announces Data Presented From Two Posters Regarding Preclinical Activity Of Azenosertib In Triple-Negative Breast Cancer At 2026 American Association For Cancer Research

Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment

04-18 03:20

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

04-17 19:15

美股大行评级 | 大砍54%！大摩下调Robinhood 目标价从147降至95美元；星座品牌酒业(STZ)获8家大行上调目标价

今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9.5美元升至9.75美元；Citizens：维持戴夫"跑赢大市"评级，目标价从310美元升至335美元

04-13 14:07

What's Behind The Surge In Zentalis Stock?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) shares are surging Friday after a Guggenheim analyst raised the price target from $6 to $10.

04-11 00:44

美股牛股 | ZNTL飙升60%，卵巢癌临床试验获重大突破；IVVD大涨31%

ZNTL飙升60%，卵巢癌临床试验获重大突破；IVVD大涨31%，就儿科临床研究与FDA达成一致；EOSE大涨近30%，Q1财报强劲，营收创新高>>

04-10 19:22